Everolimus for patients with metastatic renal cell carcinoma (mRCC) refractory to anti-VEGF therapy: Preliminary results of a pooled analysis of noninterventional studies.
Laurence Albiges
Consultant or Advisory Role - Astellas Pharma; Novartis; Pfizer
Honoraria - Novartis
Research Funding - Novartis
Lothar Bergmann
Honoraria - Novartis
Jean-Christophe Eymard
Honoraria - Novartis; Sanofi
Manuela Schmidinger
Consultant or Advisory Role - Astellas Pharma; GlaxoSmithKline; Novartis; Pfizer; Roche
Honoraria - Astellas Pharma; GlaxoSmithKline; Novartis; Pfizer; Roche
Research Funding - Pfizer; Roche
Expert Testimony - Pfizer (U)
Aristotelis Bamias
Consultant or Advisory Role - GlaxoSmithKline; Novartis; Pfizer; Roche
Honoraria - Bayer; GlaxoSmithKline; Novartis
Research Funding - GlaxoSmithKline; Pfizer; Roche
Meryem Ktiouet
Employment or Leadership Position - Novartis
Gregor Fischer
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Despoina Xanthaki
Employment or Leadership Position - Novartis
Gernot Guderian
Employment or Leadership Position - Novartis